420 with CNW — State of the State Addresses Full of Praise for Marijuana Programs

Governors from different states in the country have been proclaiming their cannabis reform plans and accomplishments as part of their annual budget requests and State of the State speeches. The proposals and statements from state executives show how marijuana has grown more mainstream, as its being discussed in venues alongside infrastructure, education and taxes.

Below are some of the things governors said about cannabis in 2022.

South Dakota

Gov. Kristi Noem of South Dakota is focused on the proper implementation of the state’s medical marijuana program, which was recently launched. In an interview, Noem stated that she was focused on ensuring that the state had the most responsible, safe and well-run medical marijuana program in the country.

Virginia

Ralph Northam, the former governor of Virginia, discussed the criminal justice implications of Virginia’s move to legalize marijuana in 2021 during his final address earlier this month, thanking lawmakers who supported the reform. The state’s current governor, Gov. Glenn Youngkin, noted that before creating a market for commercial cannabis sales and production, some work needed to be done.

Rhode Island

Gov. Dan McKee included a measure to legalize cannabis as part of his annual budget plan this year, which makes it the second time he has done so. If approved, the measure mandates that automatic marijuana expungements occur in the state. This is in addition to allowing individuals aged 21 and above to possess and buy up to an ounce of marijuana and store up to five ounces of cannabis in their primary residencse.

The measure will also apply a weight-based excise tax on cannabis growing, a retail excise tax of 10% and sales tax upon marijuana transactions.

New York

Earlier this month, Gov. Kathy Hochul of New York announced plans to establish a $200 million public-private fund that will promote social equity in the state’s flourishing cannabis market. The governor highlighted the importance of creating opportunities for all individuals in the state, in particular, those from historically marginalized communities.

Projections show that the state’s cannabis market will generate billions in revenue, especially after marijuana business licenses are approved.

New Mexico

In her State of the State speech, Gov. Michelle Lujan Grisham of New Mexico discussed the economic potential of the cannabis industry under the legalization initiative she signed in 2021. The state plans to expand its economic footprint in communities and create thousands of employment opportunities as well as revenue to support local services in the state.

Given the multifaceted effects that the products of cannabis companies such as RYAH Group Inc. (CSE: RYAH) are triggering in people’s lives, it isn’t surprising that many state governors are touting the successes of this nascent industry.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Spanish Study Finds That Young Cannabis Users Enjoy Better Sexual Function, Orgasms

According to a Spanish study published in December 2021, young people who smoke cannabis and consume alcohol tend to enjoy an overall superior sexual function and orgasms when compared to their peers who don’t smoke cannabis or don’t drink alcohol.

The research team was motivated to undertake this study because much of the existing scientific data on this subject tended to be contradictory, with some studies indicating that marijuana consumption improved sex life while others concluded that smoking marijuana had a detrimental effect on an individual’s sex life. The team based at Almeria University decided to design its own observational study in order to assess the effects of cannabis consumption on sexual function. The team opted to use the top three frequently used surveys that help in identifying potentially risky cannabis and alcohol use, in addition to ascertaining what effects that had on sexual function.

In the first six months of 2020, a total of 89 males and 185 females were assessed in accordance with the study design of the research team. These individuals were all in the age bracket of 18 to 30 years of age, and each participant was either a regular marijuana user or a regular user of alcohol or they didn’t use either of the two substances of interest. The team excluded anyone who had diabetes, high blood pressure and other conditions that could impact the person’s sexual function. Those using other substances such as MDMA or opiates were also excluded.

The researchers found that the individuals categorized as being in the high-risk group of cannabis consumers yet belonging to the moderate risk group of alcohol users exhibited better sexual function and orgasms. Additionally, individuals who used alcohol a lot tended to report a lower sexual function when compared to the marijuana high-risk group.

The University of Almeria team posits that cannabis helps to remove shame and anxiety, which could explain why high-risk users of this substance report better sexual function and orgasms. The researchers didn’t observe any significant differences between the sexual function of females and that of males in the study.

The team believes that by focusing on a younger demographic, they may have found the reason why previous studies on the subject reported contradictory findings. This is because older study subjects, especially males, were prone to declining sexual function, unlike the 18 to 30 year-old group, which rarely reports cases of erectile dysfunction.

The researchers note that future studies need to explore any potential effects on sexual function and orgasms among cannabis and alcohol users with respect to the different kinds of relationships, such as long-term relationships vs. sporadic or one-off encounters.

Such studies on marijuana would be further enriched if they made use of some of the existing hi-tech devices such as the RYAH Smart Inhaler manufactured by RYAH Group Inc. (CSE: RYAH) while documenting the precise dosage of marijuana that participants are taking during the sessions of interest.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Mississippi Mom Believes Legalizing Medical Cannabis Would Transform Epileptic Daughter’s Health

We don’t know a lot about how cannabis affects the body, although anecdotal accounts and preliminary research shows that cannabis has some therapeutic ability. However, the consensus among most experts is that we need more research on cannabis. In the meantime, what we do know about the controversial plant is significant enough.

Studies have found that cannabis can reduce seizures suffered by children with intractable epilepsy. Furthermore, the FDA has approved a CBD-based drug called Epidiolex to treat two rare and severe forms of pediatric epilepsy: Dravet Syndrome and Lennox Gastaut Syndrome.

Gaining access to such cannabis-based epilepsy drugs is an entirely different story. As it stands, 36 states have legalized medical cannabis use. While that may seem like a lot of states, millions of Americans still cannot access medical cannabis. In Ocean Springs, Mississippi, Allie Byrd waits with bated breath as the conversation around medical cannabis in Mississippi continues. Her five-year-old daughter Avalyn May suffers from an ultra-rare disorder that causes daily seizures and requires a ton of seizure medication to alleviate.

In a Facebook post that has now been shared hundreds of times, Byrd says she noticed something was amiss in 2018. After exhibiting symptoms including chronic vomiting, Avalyn May was diagnosed with a super-rare genetic brain disorder called STXBP1. The condition is so rare that only around 800 children in the entire world have it. Avalyn May has to take 16 pills every day to control the condition. She became a nonverbal child after the seizures started, and although the medications reduce the number of seizures she suffers, they have serious side effects.

After joining a group for parents whose children had the same genetic disorder, Byrd became close to a parent who informed her of THC’s potential in curing seizures. The parent moved to Colorado, where both medical and recreational cannabis are legal, and put her child on a THC treatment. Except for monthly flare ups, the child is “almost entirely” cured of the seizures and doesn’t use any seizure medication. With this information, Byrd hopes that her daughter will also respond positively to a cannabis-based treatment.

Unfortunately, Mississippi still doesn’t have a medical cannabis program. Although voters approved medical marijuana in the 2020 ballot, the vote was overturned by the Supreme Court due to a procedural issue. Governor Tate Reeves and the legislature are currently debating the details of the final medical cannabis bill. If passed, the bill will be life-changing for little Avalyn May, Byrd says. In the meantime, all she can do is hope.

If the cannabis legalization bill is eventually passed, patients such as Avalyn May could potentially benefit by taking their cannabis medicine with the help of state-of-the-art dose measuring devices, such as those commercialized by entities like RYAH Group Inc. (CSE: RYAH).

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Eight Marijuana Trends Likely to Play Out in 2022

Marijuana industry executives should pay attention to both positive and negative trends in the industry this year. While some will be a continuation from last year, some will be new to the industry. Below is a list of some trends to be on the lookout for this year.

More states will legalize cannabis.

More states are expected to legalize cannabis this year, including Delaware, Maryland and Rhode Island, which may legalize the herb for recreational use. States such as North Carolina, South Carolina, Kansas and Mississippi are also expected to legalize cannabis for medical use.

However, the federal government’s stance on the herb’s legalization may remain unchanged.

Unpredictability of climate change will continue.

Weather patterns have become unreliable due to climate change, which means marijuana cultivators need to become adaptable and flexible. Severe flooding, drought, hurricanes, early freezes and wildfires should all be watched closely by cannabis growers.

The industry’s reputation will be cemented as recession proof.

Even with more coronavirus variants developing, cannabis sales at the retail level are expected to remain strong, as they have throughout the pandemic. While the pandemic does present both unexpected and expected challenges for the operational side of marijuana companies, consumers will continue visiting retailers as the market grows.

Inaccurate profitability and growth assumptions in Canada will continue.

Some CEOs of publicly traded Canadian companies will continue making incorrect assumptions about the expected profitability and growth of their businesses as well as about the pace of the global legal marijuana market’s growth and development. It would be fascinating to track this as well in the United States.

More firms will demand lower taxes.

The states of California and Alaska are two markets where state-imposed taxes are a point of contention. For instance, companies participating in the marijuana market in California warn that heavy taxes may cause the market’s collapse, with a recent letter sent to Gov. Gavin Newsom highlighting that if meaningful changes weren’t made, most companies would be faced with the choice of paying their employees or paying extortionate taxes to a system that’s been designed to fail. Over in Alaska, an $800 growing tax has imposed financial strains on cultivators. Players in other cannabis markets are likely to call for reduced taxes so that the industry can thrive.

More cities and towns in California will embrace the industry.

It is expected that more municipalities in this particular state will embrace the licensed cannabis industry.

Brands will grow across various sectors.

As more brands set up their own operations and find ways to work with partners in other states, this trend is expected to grow. Thus far, we’ve observed some edibles and flower brands such Wana Brands expand across the United States and internationally.

Mergers and acquisitions will continue

These deals are set to continue at a fast pace in the United States, especially in states with newly legal marijuana markets. The newly opened markets are likely to create an additional user-base for technology and devices, such as those from RYAH Group Inc. (CSE: RYAH), which facilitate the use of marijuana as a medicine.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Federal Agency Announces Funding for Research into Drug-Harm-Reduction Approaches

The National Institutes of Health is promoting research into the effectiveness of various harm-reduction strategies, which include safe consumption facilities and drug decriminalization, as part of its effort to fight the opioid epidemic. The federal health agency released requests for applications last week for an effort that will generate funding for studies on how safe consumption sites and other harm-reduction strategies can be used to address the overdose crises.

The agency seeks to launch a Harm Reduction Network that will grow the understanding of the implementation, impact and effectiveness of new and existing harm-reduction strategies in order to address substance use disorder and the opioid epidemic more broadly.

A counterpart request for application requests the establishment of a coordination center in the network, which will offer coordination and logistical support, clinical practice and research resources, data sharing and data harmonization supports.

The agency is accepting applications for projects that entail the expansion of the delivery models and settings through which harm-reduction policies are established; the development and testing of new harm-reduction practices; the assessment of the impact of new harm-reduction strategies that have been implemented at the local and state levels; and implementation of new and existing harm-reduction policies effectively.

In its notice, the agency states that harm-reduction strategies are aimed at minimizing or preventing adverse outcomes associated with substance use, including the transmission of infectious diseases as well as nonfatal and fatal overdoses. The ageny highlights examples of existing harm-reduction services, which include HIV and Hepatitis C virus testing, sterile syringes, safer smoking equipment, fentanyl test strips and naloxone.

This is in addition to noting that the Office of National Drug Control Policy is focused on the prioritization of harm-reduction policy, as a way to prevent overdoses.

Component agencies of the NIH, including the National Institute on Drug Abuse, state that emerging harm-reduction strategies include the authorization of safe consumption facilities, prosecutor and police-driven diversion and deflection efforts, and the decriminalization of certain drugs.

Nora Volkow, director of NIDA, has repeatedly voiced concerns about the harms caused by drug criminalization. Last year, Volkow revealed that she was open to exploring how support systems could help individuals obtain treatment, hinder them from getting infected with HIV, and prevent overdoses and death.

In November 2021, the city of New York established the first safe consumption facility in the country. Advocates wonder how the government will react to this, as it recently blocked Safehouse, a not-for-profit in Philadelphia, from establishing a harm-reduction facility.

There is hope that such federally backed studies could tilt the tide in favor of ending prohibition so that more people can enjoy the benefits of various innovative products such as the RYAH Smart Inhaler from RYAH Group Inc. (CSE: RYAH) intended to bring precision to the measurement of plant medicine doses.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — NYC Officials Admit Safe-Consumption Sites Already Paying Off

The opioid pandemic has wreaked havoc across America for decades, taking hundreds of thousands of lives from 1999 and leaving millions of Americans with substance use disorder. The prevalence of pharmaceutical drugs as well as the increased accessibility of illicit drugs such as heroin has made it nearly impossible to effectively end the opioid crisis. And since addiction and drug use tends to have extremely negative stereotypes, addicts tend to shy away from seeking treatment.

For several lawmakers and drug reform groups, the first thing to do was reduce opioid deaths. From April 2020 to April 2021, America lost an estimated 100,000 people to opioid overdoses, significantly underscoring the need for immediate action. Ironically, one of the most controversial solutions to opioid deaths —safe-consumption sites — has proven to be quite effective at preventing individuals from succumbing to opioid overdoses. These sites are locations where people suffering from drug addiction can consumer illicit drugs under the supervision of trained medical professionals to prevent overdose deaths.

New York City was the first city in the country to launch an Overdose Prevention Center. According to the New York City Health Department, these harm-reduction centers have been used more than 2,000 times and prevented at least 59 overdose deaths so far. The initial results have been quite promising, Health Commissioner Dave Chokshi said in a press release, with the harm-reduction centers reducing “needless suffering and avoidable death.”

The simple, indisputable truth is that safe-consumption sites save lives, Chokshi says. For years, drug reform advocates have argued that such sites could be instrumental in helping America combat the opioid overdose epidemic and reduce the stigma associated with substance misuse disorders. Destigmatizing such disorders will make people a lot more comfortable with seeking treatment before it’s too late. Sam Rivera, the executive director of OnPoint NYC, which runs a safe consumption site, says the group is trying to humanize people who, in many cases, aren’t treated as human.

The New York City Board of Health recently approved a resolution that outlined the evidence showing just how effective a harm-reduction approach, rather than criminal justice, can be. The unanimously approved resolution also urged New York State and the federal government to provide authorization for harm-reduction centers as well as expand funding and support for the harm-reduction approach.

There may be some benefit to determining how this harm-reduction effort can benefit from cutting-edge devices such as the smart inhalers and dose-measuring devices commercialized by companies such as RYAH Group Inc. (CSE: RYAH) since the technology has the capacity to regulate the dosage consumed.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Weed 6: CNN Shines the Light on Medical Cannabis for Autistic Kids

Cannabis may still be one of the most controversial plants in America’s history, but awareness of its potential medical abilities is steadily increasing. First legalized for medical use by California in 1996, medical cannabis is now legal in 36 states and used to alleviate medical conditions such as chronic pain, cancer and cancer treatment symptoms, epilepsy, glaucoma and Alzheimer’s disease. Thanks to the plant’s potent medical properties, researchers all over the world are constantly running studies to discover the breadth of marijuana’s medical potential.

A pediatric clinical trial at UC-San Diego’s Center for Medical Cannabis Research has found that cannabidiol (“CBD”), one of the many chemical compounds produced by hemp and marijuana, has a positive effect against some of the more extreme symptoms of autism. Autism is a neurodevelopmental disorder that usually results rigidity and repetitive behaviors as well as difficulty understanding nonverbal communication and social interaction. The disorder affects one in 44 children in America and can be accurately diagnosed by the time a child is two years old.

Autism exists on a spectrum, with some people exhibiting mild, easy-to-manage symptoms and others being completely nonverbal and, in some cases, aggressive and violent. It can also lead to self-harm and extremely disruptive behavior in extreme cases. According to Dr. Doris Trauner a distinguished professor of neurosciences and pediatrics at the University of California, San Diego, “aggression and self-injurious behaviors” are common in children with severe autism. People with less severe autism may have trouble communicating in social settings, she told CNN chief medical correspondent, Dr. Sanjay Gupta, even if they are capable of speaking quite well.

For example, Ezra Fouquette started exhibiting unusual behavior when he was 17 months old, and he was diagnosed with autism disorder five months later. He soon became aggressive and violent, says Joan Fouquette, his mother. She didn’t want to put him on available pharmaceutical therapies because they can have side effects. This includes an increased risk of developing diabetes, obesity and cardiovascular-type issues. Instead, Fouquette tried a variety of unsuccessful homeopathic remedies and therapies until she heard about the CBD clinical trial at UC San Diego.

She enrolled Ezra into the double-blind placebo-controlled study when he was nine years old. Researchers gave CBD and a placebo to the participants at random and studied their brains to see how cannabidiol affected them. Ezra received both CBD and a placebo during the clinical trial, and after a few weeks, the once nonverbal young boy was singing. He’s not aggressive anymore, Fouquette says, and she can now communicate with him in a way she never could. A year after the study concluded, Ezra is still a happy and communicative young boy.

The study still hasn’t been published, however. Additionally, a lot more research is still needed before CBD is developed into a legal behavioral drug for autistic kids. Such additional research would greatly benefit from making use of advanced dose-measuring devices such as the internet-enabled smart inhalers manufactured by RYAH Group Inc. (CSE: RYAH) since it would help to standardize the dose administered to participants during clinical trials.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Does CBD Support Post-Cancer Recovery?

You have probably heard about CBD, either from the media or in person, especially in regard to its medical potential. Cannabidiol (“CBD”) came into the limelight when the 2018 farm bill federally legalized the cultivation and sale of industrial hemp and its derivatives, including CBD. Although hemp is in the cannabis family, CBD extracted from legal industrial hemp will not intoxicate you. However, CBD still shares plenty of medical properties with THC, the main psychoactive agent in marijuana, and several studies have found that cannabidiol can aid in post-cancer recovery.

So how exactly does taking CBD aid in post-cancer recovery? It all boils down to potent anti-inflammation and antioxidant properties. CBD is most commonly used to address issues such as chronic pain, anxiety, depression, nausea and insomnia. Some studies have also found that cannabinoids such as CBD can inhibit tumor growth and reduce tumor invasion. However, more research is needed before we can conclusively state that CBD is an effective anti-cancer treatment. However, at the moment, cannabinoid does look to be able to  support post-cancer recovery.

Coincidentally, most of the adverse symptoms caused by cancer treatments such as radiation and chemotherapy can be treated by CBD treatment. These symptoms include nausea, insomnia, loss of appetite and neuropathic pain. Recovering from cancer can be brutal as the treatments aren’t easy on the body. Lack of appetite, for instance, can significantly reduce your food intake, reducing your energy levels and actually hindering your recovery. Since CBD is known to stimulate appetite, individuals undergoing cancer treatment can use it to maintain sufficient nutrient intake and give their bodies the energy it needs to recover.

This is the same for insomnia, which will not only make you feel tired and fatigued but can also put your health at even more risk. CBD is also thought to be a pain reliever, and it can be effective against the sometimes severe pain cancer patients feel. All cannabinoids, including CBD and THC, create their therapeutic effects by interacting with the endocannabinoid system (“ECS”), a part of the nervous system that’s in charge of regulating processes such as hunger, sleep and pain. Essentially, the ECS is a system that works to maintain homeostasis, or the body’s internal balance.

If you would like to use CBD to aid in cancer recovery, make sure to speak to your doctor first. Additionally, you should not ditch your cancer medication for CBD; while some studies have found that it has anti-cancer effects, it isn’t an effective treatment against cancer.

Such cannabis-based treatments may stand a higher chance of being beneficial when taken using an IoT-enabled dose-measuring device such as those produced by RYAH Group Inc. (CSE: RYAH) and other such companies.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) to Collaborate with OMNI Medical Services for Cannabis Study in Treatment of COVID-19

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, has announced plans for a U.S. clinical study focused on treatment COVID-19. RYAH will be partnering with OMNI Medical Services to perform the U.S.-based clinical study evaluating patients using inhalation of medical cannabis to both treat and prevent the coronavirus. The study, which will run for five years, will involve the use of RYAH’s Smart Inhaler devices and will involve up to 11,000 of OMNI’s patients across the country. Phase 2 of the study is planned for Q2 2022, with an end date in 2024. The strategic plan also includes presenting gathered data to the FDA as part of the effort for national legalization of cannabis for medical use. “We’re excited to be working with OMNI on this thoughtful and timely study on the evaluation of novel preventative and treatment measures related to inflammatory effects from COVID-19,” said RYAH Group CEO Gregory Wagner in the press release. “RYAH is honored to be selected to participate in this important project with OMNI, to be contributing to valuable data aggregation, and to raise our understanding of plant-based inhalation methods on potentially addressing anti-inflammatory effects of COVID-19.”

To view the full press release, visit https://cnw.fm/ODy0V

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies, as well as licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. For more information about the company, please visit www.RyahGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW — Patients, Doctors Now Discussing Medical Marijuana

Cannabis has always been a controversial topic. Even as dozens of states passed medical cannabis regulations and more studies found that the plant had plenty of medical potential, the stigma around cannabis remained. Not only did this prevent important conversations surrounding topics such as the disproportionate effects of cannabis prohibition from happening early enough, but it also kept patients from talking about cannabis with their doctors, even if they stood to benefit a great deal from marijuana-based treatment. However, results from a new survey indicate that this may be changing.

Healthcare company Cannaceutica conducted a survey of 445 healthcare providers and asked them whether their patients had talked to them about cannabis or requested medical marijuana treatments in the past 30 days. More than 70%  said their patients had made inquiries about cannabis treatments in the past month, with the patients asking about cannabis far more often compared to other alternative pain treatments such as physical therapy, massage and acupuncture. The healthcare providers who took part in the online survey included general practitioners, nurse practitioners, rheumatologists, pain-management specialists and neurologists.

The results of the survey reveal a drastic shift in how people view cannabis. Traditionally, patients who could benefit from cannabis treatments have refrained from asking their doctors about medical marijuana for fear of being seen as potheads or being dropped by their doctors. Similarly, health practitioners weren’t comfortable discussing cannabis with their patients as it is still federally prohibited and hasn’t been sufficiently studied and researched. In fact, national polls from 2018 and 2019 revealed that less than 40% of patients discussed cannabis use with their doctors.

Fortunately, today more patients are willing to raise the option of medical cannabis treatments with their healthcare providers. According to Cannaceutica’s survey, 81% of healthcare providers believe cannabis will play a role in chronic pain management in the future. Still, only one person in four healthcare practitioners would recommend medical marijuana to their patients currently, mostly due to the scarcity of reliable cannabis research as well as the legal and regulatory issues surrounding the plant. With several lawmakers working to pass legislation that would federally decriminalize cannabis, there is a chance the federal government could legalize cannabis in the near future.

If that happens, 74% of the survey participants said they would endorse a medical cannabis treatment plan. They would also be more comfortable recommending medical marijuana if there was more scientific research and documentation about the benefits and risks of using cannabis as a chronic pain treatment. At the moment, 64% said they obtained most of the cannabis information they knew from their patients, 44% from the internet and 40% from medical journals.

Now that patients are talking to their doctors about medical cannabis, it may not be long before cutting-edge enabling technology such as the smart inhalers manufactured RYAH Group Inc. (CSE: RYAH) become commonplace among patients who are collaborating with their doctors on matters of managing various health conditions.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.